L26/O-179 ACMG/AMP-guided discovery of regulatory CLPP and GPX4 risk variants in non-obstructive azoospermia with concordant testicular transcript–protein depletion
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.177 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von P. Paladhi und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Do ACMG/AMP (2015)–prioritized regulatory variants in CLPP and GPX4 associate with NOA and demonstrate concordant testicular downregulation? Summary answer Yes; PS4-enriched CLPP/GPX4 variants with PP3-supported regulatory/splicing disruption were associated with NOA and accompanied by reduced testicular expression. What is known already Non-obstructive azoospermia (NOA) remains idiopathic in a substantial proportion of men even after exclusion of established genetic etiologies. Our group previously demonstrated that novel mutations in the Y-chromosomal spermatogenic regulator gene TSPY1 are significantly associated with spermatogenic failure in Indian Bengali men, supporting a population-specific genetic susceptibility framework. Beyond Y-linked regulation, spermatogenesis depends on mitochondrial proteostasis (CLPP) and redox homeostasis (GPX4), processes that shape germ-cell survival and differentiation. Importantly, non-coding variants can alter promoter/TF occupancy and RNA-binding/splicing motifs, providing plausible mechanisms for transcript dysregulation, yet integrated evidence in South Asian cohorts remains limited. Study design, size, duration This is a case–control study conducted between March 2018 to July 2025 in an Indian Bengali population. Genomics arm: 206 clinically confirmed NOA men and 218 proven fertile, age- and ethnicity-matched controls; NOA cases were screened negative for Yq microdeletions. Tissue arm: limited TESA subset comprising 18 NOA testes compared with 14 obstructive azoospermia (OA) testes used as tissue controls for expression and protein-level comparisons. Participants/materials, setting, methods Peripheral blood genomic DNA was subjected to locus-specific PCR followed by bi-directional Sanger sequencing with chromatogram-level curation and reference-based alignment. Variants were interpreted using ACMG/AMP (2015), prioritizing PS4 (statistically increased prevalence in cases) and PP3 (multiple computational lines supporting regulatory/splicing impact). Functional annotation incorporated MutationTaster (prediction/score), RegulationSpotter (promoter/TFBS overlap with quantitative scores), and SpliceAid (RNA-binding/splicing factor motif gain/loss). Testicular protein localization by immunohistochemistry and quantitative abundance by ELISA were performed comparing NOA with controls. Main results and the role of chance In the genomics arm, significant case enrichment was observed for non-coding variants in CLPP and GPX4, supporting a strong PS4 signal under ACMG/AMP (2015). For CLPP, intronic indels clustered within splice-proximal regions and showed robust associations, including OR074513 (delC, intron 2–3; p = 0.0031), OR873654 (insG, intron 2–3; p = 0.0045) and OR873655 (insA, intron 3–4; p = 0.0019), suggesting a regulatory hotspot within the intronic architecture of CLPP. For GPX4, two discrete intronic clusters were evident: intron 1–2 variants OQ939947 (G>T; p = 0.0006) and OR381683 (G>A; p = 0.0011), together with an intron 4–5 variant OR037273 (delA; p = 0.0017), consistent with multiple regulatory loci influencing gene control. All prioritized variants received maximal MutationTaster scores (0.9999) and mapped to regulatory contexts by RegulationSpotter, including promoter/TFBS overlap for GPX4 OQ939947 (score 82.28) and regulatory overlap for CLPP OR873654 (score 43.66). SpliceAid further supported mechanistic plausibility through motif rewiring, notably gain of TIA-1/TIAL1 binding for OQ939947 and loss of hnRNP A1 binding for OR873655. In the TESA subset (18 NOA vs 14 OA controls), protein-level analyses demonstrated concordant depletion of CLPP and GPX4 in NOA relative to OA on immunohistochemistry and ELISA, aligning genetic enrichment with tissue-level molecular deficiency. Limitations, reasons for caution TESA validation was performed in a small subset (18 NOA vs 14 OA) and OA tissue controls may not fully substitute for proven fertile testes. In-silico regulatory/splicing predictions strengthen biological plausibility but do not establish causality; population-frequency confirmation and mechanistic assays are needed. Independent replication in larger cohorts is required. Wider implications of the findings Integrating case–control enrichment with ACMG/AMP (2015) interpretation and regulatory/splicing annotation, with concordant testis-level depletion, implicates CLPP and GPX4 in NOA. Alongside our prior TSPY1 findings, this supports a population-relevant molecular framework and motivates targeted panels and functional validation to refine counselling and stratification. Trial registration number No
Zitieren
APA
Paladhi, P., Dutta, S., Pal, S., Alam, M., Ghosh, P., Sharma, S., Chattopadhyay, R., & Ghosh, S. (2026). L26/O-179 ACMG/AMP-guided discovery of regulatory CLPP and GPX4 risk variants in non-obstructive azoospermia with concordant testicular transcript–protein depletion. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.177
Vancouver
Paladhi P, Dutta S, Pal S, Alam M, Ghosh P, Sharma S, et al. L26/O-179 ACMG/AMP-guided discovery of regulatory CLPP and GPX4 risk variants in non-obstructive azoospermia with concordant testicular transcript–protein depletion. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.177
BibTeX
@article{Paladhi2026,
author = {Paladhi, P. and Dutta, S. and Pal, S. and Alam, M. and Ghosh, P. and Sharma, S. and Chattopadhyay, R. and Ghosh, S.},
title = {L26/O-179 ACMG/AMP-guided discovery of regulatory CLPP and GPX4 risk variants in non-obstructive azoospermia with concordant testicular transcript–protein depletion},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.177}
}
EUVIMED